{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:15:53Z","timestamp":1790500553485,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaad.2018.07.048","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T05:25:23Z","timestamp":1533533123000},"page":"158-167.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis"],"prefix":"10.1016","volume":"80","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Petro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gadkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2018.07.048_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2133.2003.05092.x","article-title":"Prevalence of atopic dermatitis in Japanese adults","volume":"148","author":"Muto","year":"2003","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.048_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.048_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.048_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study","volume":"135","author":"Silverberg","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.048_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/sj.jid.5700587","article-title":"Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood","volume":"127","author":"Barker","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.048_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00128071-200809010-00005","article-title":"Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD Index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis","volume":"9","author":"Hon","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.048_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.048_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jaad.2018.07.048_bib9","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.048_bib10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis (AD) skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.048_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"10.1016\/j.jaad.2018.07.048_bib12","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"MacDonald","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"10.1016\/j.jaad.2018.07.048_bib13","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"PNAS"},{"issue":"10013","key":"10.1016\/j.jaad.2018.07.048_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.048_bib15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"10.1016\/j.jaad.2018.07.048_bib16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10086","key":"10.1016\/j.jaad.2018.07.048_bib17","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.048_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10039","key":"10.1016\/j.jaad.2018.07.048_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jaad.2018.07.048_bib20","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jaad.2018.07.048_bib21","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.048_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2018.07.048_bib23","series-title":"Dupilumab efficacy and safety in adult patients with active eosinophilic esophagitis: a randomized double-blind placebo-controlled phase 2 trial","author":"Hirano","year":"2017"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.048_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.048_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pervac.2011.05.002","article-title":"Vaccine immunology","volume":"1","author":"Leo","year":"2011","journal-title":"Perspect Vaccinol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.048_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40413-016-0120-5","article-title":"International consensus (ICON): allergic reactions to vaccines","volume":"9","author":"Dreskin","year":"2016","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.048_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1203\/PDR.0b013e3182072229","article-title":"Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal \u03c9-3 fatty acid supplementation during pregnancy and lactation","volume":"69","author":"Furuhjelm","year":"2011","journal-title":"Pediatr Res"},{"issue":"6 Pt 1","key":"10.1016\/j.jaad.2018.07.048_bib28","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1067\/mai.2000.105804","article-title":"Development of immunologic memory against tetanus toxoid and pertactin antigens from the diphtheria-tetanus-pertussis vaccine in atopic versus nonatopic children","volume":"105","author":"Holt","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.048_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.immuni.2006.02.006","article-title":"Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus","volume":"24","author":"Howell","year":"2006","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.048_bib30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jaci.2010.08.010","article-title":"Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls","volume":"126","author":"Schneider","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 78","key":"10.1016\/j.jaad.2018.07.048_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1398-9995.2004.00569.x","article-title":"Consensus guidelines in diagnosis and treatment of atopic dermatitis","volume":"59","author":"Eichenfield","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2018.07.048_bib32","series-title":"Adacel\u00ae [package insert]","year":"2013"},{"key":"10.1016\/j.jaad.2018.07.048_bib33","series-title":"Menomune\u00ae [package insert]","year":"2013"},{"key":"10.1016\/j.jaad.2018.07.048_bib34","first-page":"271","year":"2014"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.048_bib35","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"40","key":"10.1016\/j.jaad.2018.07.048_bib36","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1016\/j.vaccine.2011.07.055","article-title":"Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children","volume":"29","author":"Hendrikx","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.048_bib37","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1128\/IAI.68.7.3873-3877.2000","article-title":"Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized","volume":"68","author":"Rowe","year":"2000","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.jaad.2018.07.048_bib38","doi-asserted-by":"crossref","first-page":"8130","DOI":"10.1128\/IAI.73.12.8130-8135.2005","article-title":"Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children","volume":"73","author":"Rowe","year":"2005","journal-title":"Infect Immun"},{"issue":"1-2","key":"10.1016\/j.jaad.2018.07.048_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2013.01.001","article-title":"CD4 T-helper cell cytokine phenotypes and antibody response following tetanus toxoid booster immunization","volume":"390","author":"Livingston","year":"2013","journal-title":"J Immunol Methods"},{"issue":"24","key":"10.1016\/j.jaad.2018.07.048_bib40","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1001\/jama.293.24.3003","article-title":"Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults","volume":"293","author":"Pichichero","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.048_bib41","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832351X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832351X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:47:57Z","timestamp":1759272477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221832351X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S019096221832351X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.048","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}